Weikang Pharmaceutical (300878.SZ) released its 2023 annual report. The company achieved revenue of 520 million yuan during the reporting period, a decrease of 2.41% over the previous year. The net loss attributable to shareholders of the listed company was RMB 8,038,600, a year-on-year change of profit to loss. The net loss attributable to shareholders of the listed company after deducting non-recurring profit and loss was 25.217,500 yuan, a year-on-year profit to loss. Basic earnings per share - 0.06 yuan/share, and it is proposed to distribute a cash dividend of 2.50 yuan (tax included) for every 10 shares to all shareholders.
维康药业(300878.SZ)发布2023年度业绩，净亏损803.86万元，同比盈转亏
Weikang Pharmaceutical (300878.SZ) announced its 2023 annual results, with a net loss of 8.038,600 yuan, a year-on-year profit to loss
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.